{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-nail-infection/prescribing-information/oral-terbinafine/","result":{"pageContext":{"chapter":{"id":"7009ace0-8da0-5da4-917e-8900ae3cc390","slug":"oral-terbinafine","fullItemName":"Oral terbinafine","depth":2,"htmlHeader":"<!-- begin field 638e556d-ce29-4fa5-9425-3f38b2a825f5 --><h2>Oral terbinafine</h2><!-- end field 638e556d-ce29-4fa5-9425-3f38b2a825f5 -->","summary":"","htmlStringContent":"<!-- begin item 7c2d94af-f416-4a42-9a69-2706d527790a --><!-- end item 7c2d94af-f416-4a42-9a69-2706d527790a -->","topic":{"id":"1303927b-7e0c-517d-85e9-841c9ac02151","topicId":"d2c6135f-fef1-4a56-80dc-161c93380c7d","topicName":"Fungal nail infection","slug":"fungal-nail-infection","lastRevised":"Last revised in March 2018","chapters":[{"id":"bc563964-f1b0-559d-9f21-380162710ddf","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dd347390-fb63-5e80-9fab-bd3cc4704341","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0cdd100c-c9d0-5685-980c-52f246d1100e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"886d32db-68df-5055-b459-55404c1f011e","slug":"changes","fullItemName":"Changes"},{"id":"c1cacd2b-dba0-5341-a274-66fd882b2036","slug":"update","fullItemName":"Update"}]},{"id":"9f0a65a3-9309-5a00-a9fa-bda2fb7a49c4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1121797b-5555-5e24-a9ae-aabc657725dd","slug":"goals","fullItemName":"Goals"},{"id":"aa660497-e222-5e9d-b282-3069500c380f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49df22af-d1aa-56cd-b2dc-30e6ecc84ca8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a79a5fd4-4f6a-5d37-8714-e4bd3bea76b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6db25a8b-db82-5b72-bade-fa216c349fd8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2515b15e-47ac-5e93-acaf-588daa2e06f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d257da5b-218f-50fc-96b1-55ec4b44f5cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ccd879d-9979-5f0b-b655-8da37ca04149","slug":"definition","fullItemName":"Definition"},{"id":"20d20421-b2ba-513f-87b5-3fad4f731aa5","slug":"causes","fullItemName":"Causes"},{"id":"3142330a-0287-5835-8a69-857972828fb2","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"29b083db-9488-5407-92df-43f4952d8df3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d7dd4e0b-6a97-5db7-bfa3-aa690c7974af","slug":"complications","fullItemName":"Complications"},{"id":"3a29be3f-ea9f-56a3-b8d7-78341665856e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4346dd42-e5eb-550e-a004-7c8e7103a196","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b6a7486c-a6d8-5d8b-918c-8610bf76e212","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"eec0a81e-c0c0-5f9d-951e-f19c41cfafaf","slug":"assessment","fullItemName":"Assessment"},{"id":"d84aa70d-b236-5783-9eeb-e1181b1311f8","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"12363e3a-9d3f-54c7-8f68-1145b8f312b3","fullItemName":"Management","slug":"management","subChapters":[{"id":"36068044-ec28-5f59-b737-dd89aa53cca5","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6780cd52-ecfd-5eba-8c7e-66bc71b64ed2","slug":"topical-amorolfine","fullItemName":"Topical amorolfine"},{"id":"7009ace0-8da0-5da4-917e-8900ae3cc390","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"5d413d25-a998-5ee4-ad9d-be6306400282","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"0b102b3a-ebce-5c6e-9670-3610defc871d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bc0bd4bc-1b10-52dc-b942-cd4682774d01","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"dc202e28-37b1-5789-a14a-b5a0850d8cf8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49993e8c-ae7a-5891-bf43-21a6406ce1b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b6aa45b7-d833-599f-8bcc-4d08c6c264bb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2805cbb7-09b5-5875-a0c1-c501223c6ab3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"595745a2-d654-5e3b-850e-eac6532bd5db","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74af204e-7571-5d05-963f-0c0614335fbf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"70c00a4b-fdb4-5796-ab26-b2671fe2b6e0","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7248b534-c78e-4a8f-9173-a89a00f7f76e --><h3>Contraindications and cautions</h3><!-- end field 7248b534-c78e-4a8f-9173-a89a00f7f76e -->","summary":"","htmlStringContent":"<!-- begin item 4b0b406f-1325-4bd1-a9b1-a89a00f7f60e --><!-- begin field 73d19d25-9b85-4827-a854-a89a00f7f76e --><p><strong>Do not prescribe terbinafine to people with:</strong></p><ul><li>Hepatic impairment — the manufacturer recommends that terbinafine should not be prescribed in people with chronic or active hepatic disease. It recommends for other people, liver function tests (LFTs) should be performed. Hepatotoxicity may occur in people with and without pre-existing hepatic disease, therefore periodic monitoring of LFTs (after 4–6 weeks of treatment) is recommended. Terbinafine should be stopped immediately if LFTs are deranged.</li><li>Severe renal impairment.</li></ul><p><strong>Prescribe terbinafine with caution to people with:</strong></p><ul><li>Autoimmune disease — risk of lupus erythematosus-like effect.</li><li>Psoriasis — increased risk of exacerbation of psoriasis.</li><li>Renal impairment — the BNF recommends that half the normal dose of terbinafine should be used if estimated glomerular filtration rate (eGFR) is less than 50 mL/min/1.73 m<sup>2</sup> and there is no suitable alternative. However, the manufacturer does not recommend using terbinafine in these people, as it has not been adequately studied.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>] </p><!-- end field 73d19d25-9b85-4827-a854-a89a00f7f76e --><!-- end item 4b0b406f-1325-4bd1-a9b1-a89a00f7f60e -->","subChapters":[]},{"id":"bc11b2d8-2279-5f07-a630-182e7d4b782f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 78ba5b7b-a339-42c2-8c50-a89a00f80b23 --><h3>Adverse effects</h3><!-- end field 78ba5b7b-a339-42c2-8c50-a89a00f80b23 -->","summary":"","htmlStringContent":"<!-- begin item 5071da44-2087-4b57-971f-a89a00f809af --><!-- begin field 6a4260f3-4067-4ed0-b5b0-a89a00f80b23 --><p><strong>Adverse effects of terbinafine include:</strong></p><ul><li>Gastrointestinal — abdominal distension, dyspepsia, nausea, abdominal pain, diarrhoea, feeling of fullness (very common); pancreatitis (unknown frequency).</li><li>Nervous system — headache (common); taste disturbance (uncommon). Rarely dizziness, paraesthesia, and hypoaesthesia.</li><li>Skin and subcutaneous tissue — rash, urticarial (very common). Very rarely Stevens-Johnson syndrome, toxic epidermal necrolysis erythema multiforme, skin eruption, dermatitis exfoliative, dermatitis bullous, photosensitivity reaction, and alopecia.</li><li>Other common or very common adverse effects include arthralgia, myalgia, decreased appetite.</li><li>Other rare or very rare adverse effects include:<ul><li>Anaphylaxis.</li><li>Hepatic dysfunction, jaundice, hepatitis, cholestasis — people taking terbinafine tablets should be warned to report immediately any signs and symptoms of unexplained persistent nausea, decreased appetite, fatigue, vomiting, right upper abdominal pain, or jaundice, dark urine or pale faeces. If these symptoms develop, terbinafine treatment should be stopped, and liver function tests (LFTs) should be immediately performed.</li><li>Malaise, neutropenia, agranulocytosis, thrombocytopenia, vertigo.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>] </p><!-- end field 6a4260f3-4067-4ed0-b5b0-a89a00f80b23 --><!-- end item 5071da44-2087-4b57-971f-a89a00f809af -->","subChapters":[]},{"id":"422f9ade-30d9-5563-bd02-6f11da660374","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 81daf6b1-dd07-4d11-a9a0-a89a00f81f70 --><h3>Drug interactions</h3><!-- end field 81daf6b1-dd07-4d11-a9a0-a89a00f81f70 -->","summary":"","htmlStringContent":"<!-- begin item 8b62e5ba-e297-4537-835e-a89a00f81e0c --><!-- begin field 5e67d991-7bc7-4f7d-abb5-a89a00f81f70 --><p><strong>Possible drug interactions with terbinafine include:</strong></p><ul><li>Codeine —<strong> </strong>the analgesic effect may be reduced or abolished by terbinafine. Monitor for analgesic efficacy.</li><li>Rifampicin — levels of terbinafine are reduced. Dose increases of terbinafine may be necessary.</li><li>Tamoxifen — avoid concurrent use. Metabolism to an active metabolite of tamoxifen may be inhibited by terbinafine. </li><li>Terbinafine levels may be increased by the following drugs if taken concomitantly:<ul><li>Amiodarone.</li><li>Fluconazole, ketoconazole.</li></ul></li><li>Terbinafine may increase levels of the following drugs if taken concomitantly, thereby increasing or prolonging their effects, including adverse effects:<ul><li>Anti-arrhythmics (flecainide, mexiletine, and propafenone).</li><li>Aripiprazole, risperidone.</li><li>Beta-blockers (carvedilol, metoprolol, nebivolol, propranolol, and timolol).</li><li>Dextromethorphan.</li><li>Monoamine oxidase inhibitors Type B (MAOIs-B, such as selegiline).</li><li>Selective serotonin reuptake inhibitors (sertraline, paroxetine).</li><li>Tramadol – terbinafine may increase levels of tramadol, but not the active metabolite, which cause an increase in adverse effects, but not in analgesic effect.</li><li>Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline).</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>] </p><!-- end field 5e67d991-7bc7-4f7d-abb5-a89a00f81f70 --><!-- end item 8b62e5ba-e297-4537-835e-a89a00f81e0c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}